Skip to main content

ACR Convergence 2022 Main banner

Schedule at a Glance

Community Hub

Infection-related rheumatic syndromes

Format: Virtual Only

602: CH COVID-19:Office Hours - Advances on Use of Immunosuppression for Severe COVID-19

Monday, November 14, 2022

1:00 PM – 1:30 PM Eastern Time

All of the relevant financial relationships listed for faculty have been mitigated.

Hub Host(s)

Alfred Kim, MD, PhD

Washington University School of Medicine
St. Louis, MO, United States

Disclosure(s): Alexion Pharmaceuticals: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Aurinia Pharmaceuticals: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Exagen Diagnostics: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Foghorn Therapeutics: Grant/Research Support (Ongoing); GlaxoSmithKline: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Kypha Inc.: Consultant (Ongoing), Intellectual Property/Patents (Ongoing); Pfizer: Consultant (Ongoing)

Community Speaker(s)

Puja Mehta, MD

University College London (UCL)
london, United Kingdom

Disclosure information not submitted.
Kevin Winthrop

Oregon Health & Science University
portland, OR, United States

Disclosure(s): AbbVie: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing); Galapagos: Consultant (Ongoing); Gilead: Consultant (Ongoing); GSK: Consultant (Ongoing); Novartis: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Regeneron: Consultant (Ongoing); Roche: Consultant (Ongoing); Sanofi: Consultant (Ongoing); UCB: Consultant (Ongoing)

Advances on Use of Immunosuppression for Severe COVID-19